Pathstone Holdings’s AstraZeneca AZN Stock Holding History

Pathstone Holdings’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.6M	Buy	177,196 +6,764	+4%	+$1.27M	0.1%	145
2026 Q1	$33.6M	Sell	170,432 -23,134	-12%	-$4.46M	0.13%	118
2025 Q4	$35.6M	Buy	193,566 +20,000	+12%	+$3.51M	0.14%	111
2025 Q3	$26.6M	Buy	173,566 +5,217	+3%	+$790K	0.1%	133
2025 Q2	$23.5M	Sell	168,349 -17,517	-9%	-$2.45M	0.09%	145
2025 Q1	$27.3M	Buy	185,866 +751	+0.4%	+$109K	0.12%	130
2024 Q4	$24.3M	Buy	185,115 +11,498	+7%	+$1.61M	0.11%	129
2024 Q3	$27.1M	Buy	173,617 +5,851	+3%	+$944K	0.12%	125
2024 Q2	$26.2M	Buy	167,766 +2,965	+2%	+$446K	0.12%	126
2024 Q1	$22.3M	Buy	164,801 +58,492	+55%	+$7.75M	0.1%	134
2023 Q4	$14.3M	Buy	+106,309	New	+$13.8M	0.08%	194

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Pathstone Holdings's AZN Position: Q2 2026 in Review

Pathstone Holdings increased its AstraZeneca (AZN) stake by 4% in Q2 2026, buying an estimated $1.27M and bringing the position to 177,196 shares worth $33.6M. The position accounts for 0.1% of the portfolio, ranked #145.

Pathstone Holdings first reported a position in AZN in Q4 2023 and has held it in 11 quarters since. The position peaked at $35.6M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Pathstone Holdings held 177,196 shares of AstraZeneca worth $33.6M as of Q2 2026.
Pathstone Holdings bought 6,764 AstraZeneca shares in Q2 2026, an estimated $1.27M.
AstraZeneca made up 0.1% of Pathstone Holdings's portfolio in Q2 2026, its #145 holding.
Pathstone Holdings first reported a position in AstraZeneca in Q4 2023 and has held it in 11 quarters since.
Pathstone Holdings's AstraZeneca position peaked at $35.6M in Q4 2025.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.